Sary Alelic loss on chromosome 17 in 18 Barrett's oesophageal tumours was analysed with 17 polymorphic microsatellite markers. Loss of heterozygosity (LOH) of one or more markers was seen in 72% (13 of 18) tumours on 17p and 56% (10 of 18) on 17q. The highest 17p losses were found at D17S799 (62%, five of eight) and D17S261 (55%, five of nine), while loss at the p53 locus was 31% (5 of 16). The highest loss on 17q was found at the TCF-2 (17q11.2-q12) locus with 66% (8 of 12) LOH. TCF-2 was the only marker lost in two of the tumour samples; furthermore, TCF-2 was lost in four other tumours which retained heterozygosity at the markers on either side of it, D17S261 and D17S740. Six markers were used to assess LOH at 17q 1.2-q12, and five of eight of the tumour specimens which had LOH at TCF-2 had no other loss on 17q. No statistically significant correlations were found between loss on 17q or 17p and any clinicopathological parameters. We propose from these data that the 17qll. (Cameron and Lomboy, 1992) . During the last two decades the incidence of adenocarcinoma of the oesophagus has increased at a rate exceeding that of any other cancer, with an incidence of 500 cancers per 100 000 patients with Barrett's metaplasia per year (Haggitt, 1992 
Barrett's columnar metaplasia of the squamous epithelium of the oesophagus is a consequence of chronic gastrooesophageal reflux. It has been estimated that approxiimately 700 000 people in the United States have acquired Barrett's oesophagus (Provenzale et al., 1994) . The risk of developing adenocarcinoma of the oesophagus in these patients is 30-to 40-fold higher than in the general population (Fennerty et al., 1993; Stein and Stewart et al., 1993) . Once diagnosed, many patients with Barrett's oesophagus are entered into surveillance programmes in order to detect histopathological evidence of premalignant states, such as low-grade and highgrade dysplasia. Oesophagectomy for those observed to have early invasive carcinoma or high-grade dysplasia during such surveillance programmes results in improved survival.
A clear sequence from low-grade dysplasia to high-grade dysplasia to invasive carcinoma is observed to develop over a substantial period of perhaps 3-5 years (Cameron and Lomboy, 1992) . During the last two decades the incidence of adenocarcinoma of the oesophagus has increased at a rate exceeding that of any other cancer, with an incidence of 500 cancers per 100 000 patients with Barrett's metaplasia per year (Haggitt, 1992) .
Conventional histopathology with the detection of dysplasia is currently the only means of early diagnosis of Barrett's cancers. Oesophageal cancers share a number of molecular markers previously found in colorectal and gastric cancers, especially loss of heterozygosity (LOH) in chromosomes 5 and 17 (Vogelstein et al., 1988; Leister et al., 1990; Meltzer et al., 1991; Sano et al., 1991; Boynton et al., 1992; Huang et al., 1992; Blount et al., 1993; Meltzer et al., 1994) . In addition, overexpression and mutations of the p53 tumour-suppressor gene are a frequent event in these tumours (Baker et al., 1990; Hollstein et al., 1990; (Coles et al., 1990; Sato et al., 1990; Thompson et al., 1990) , a finding also seen in ovarian tumours (Eccles et al., 1990; Tsao et al., 1991; Foulkes et al., 1993 ). We have recently described the site of another putative tumour-suppressor gene in head and neck squamous cell carcinomas at CHRNBI (17pl2-pll.l) (Adamson et al., 1994) . Furthermore, a number of genes on 17q have previously been implicated in breast cancer, including BRCAI, NM23 and prohibitin (Hall et al., 1990; Leone et al., 1991; White et al., 1991; Futreal et al., 1994; Miki et al., 1994) . To this can be added the oncogene c-erbB-2 (17ql2), which most likely acts by increasing copy number (Van de Vijver et al., 1988) . There are a number of possible candidate genes which have been assigned to the 17qll.2-ql2 region, and these include NFI (neurofibromin 1), CSF3 (colonystimulating factor 3), erbB-2 (epidermal growth factor) and ITB4 (integrin 04). The LOH data presented in this study suggest that the TCF-2 locus may represent an important predisposing gene in Barrett's adenocarcinomas and may indicate the site of a novel tumour-suppressor gene. The importance of this finding will have to await the analysis of a larger sample of Barrett's tumours, especially when specimens containing both Barrett's premalignant and malignant tissue are investigated with these markers. Such information will further our knowledge of the clonal ordering of allelic losses in Barrett's cancers, in which it has recently been proposed that 17p allelic losses occur before 5q allelic losses during neoplastic development of this disease (Blount et al.. 1994) .
